Entries by Max

ZNF281 Emerges as a Novel Driver and Therapeutic Target in Advanced Prostate Cancer

/in /by

ZNF281 is a Krüppel-type zinc-finger transcription factor previously implicated in cancer stemness, but its role in prostate cancer has remained largely unexplored. In a new study, researchers evaluated ZNF281 expression across human prostate cancer samples, including primary tumors, metastatic lymph nodes, and normal prostate tissue. The findings revealed significantly higher expression of ZNF281 in metastatic […]

NRG1-Driven Microenvironmental Resistance to PI3K Inhibition in Prostate Cancer

/in /by

Prostate cancer is driven not only by tumor genetics but also by dynamic interactions with the tumor microenvironment (TME). Although alterations in the PI3K pathway are common, especially in PTEN-deficient disease, clinical results with PI3K inhibitors, even when combined with androgen receptor (AR) blockade, have been underwhelming. New evidence suggests that resistance may be driven […]

Arginase 1 Suppression Makes Exercise Effective Against Prostate Cancer

/in /by

Exercise has consistently been linked to improved outcomes in prostate cancer, but the mechanisms behind this effect have remained unclear. A recent preclinical study provides a compelling explanation, identifying suppression of arginase 1 (Arg1) and modulation of arginine metabolism as key drivers of exercise-induced tumor control. Using a prostate-specific Pten-knockout mouse model, researchers observed that […]

Newsletter 23/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Summer is approaching, but research never stops! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​ Clinical Research Phase 3 Trial: The PROTEUS Trial […]

IVMT-Rx-4: A New Experimental Drug That May Help Block Prostate Cancer Spread to Bone

/in /by

IVMT-Rx-4 is a preclinical stage experimental compound being studied for advanced prostate cancer, especially for cancer that spreads to bone. The basic idea is to interfere with a protein called MDA-9/Syntenin. This protein seems to help prostate cancer cells invade tissue, communicate with their environment, and settle in bone. By blocking that pathway, IVMT-Rx-4 may […]

A Promising Drug Pair for Treatment-Resistant Prostate Cancer

/in , /by

A recent preclinical study points to a potentially important strategy for advanced prostate cancer: combining two already-known drugs to attack the disease from different angles at the same time. The work focused on metastatic castration-resistant prostate cancer, one of the hardest forms of prostate cancer to treat because it often adapts after standard hormonal therapies […]

Early Phase 1 Trial of GRPR-Targeted Theranostic DOTA-STR-17126

/in , , /by

A first-in-human imaging trial of DOTA-STR-17126 just started in Australia. It is an open-label, single-arm early phase 1 study enrolling up to 20 adults with advanced or metastatic prostate or breast cancer who have exhausted standard treatments. The trial uses a theranostic approach. Participants receive gallium-68 DOTA-STR-17126 for PET imaging to detect tumors expressing the […]

Phase 2 Trial of GV20-0251 With Anti-PD-1 Therapy in mCRPC

/in , , /by

GV20-0251 is an experimental antibody that blocks a new immune brake called IGSF8, and this phase 2 study tests it together with anti-PD-1 drugs in people with advanced solid tumors that no longer respond to standard treatment. The goal is to restore early innate immune signaling so checkpoint therapy works better in resistant cancers. From […]

Zanzalintinib After Pluvicto in Chemo‑Naïve mCRPC

/in , , /by

Zanzalintinib is being tested after Pluvicto (177Lu-PSMA-617) in metastatic castration‑resistant prostate cancer (mCRPC) because it targets several escape routes tumors use once they have survived PSMA‑directed radioligand therapy and prolonged AR pathway blockade. Pluvicto delivers beta radiation to PSMA‑expressing cells, inducing DNA damage and tumor cell death, but progression still occurs and is often driven […]

UPDATE: ABBV-969 Shows Very Promising rFPS in mCRPC

/in , , /by

ABBV-969 is a dual-target antibody-drug conjugate targeting PSMA and STEAP1, data about its radiographic progression-free survival data have just been released, confirming a median rPFS of approximately 15 months in heavily pretreated metastatic castration-resistant prostate cancer. The study demonstrates a signal far exceeding the 4- to 5-month rPFS historically seen with cabazitaxel in the same […]